Sequenom Shares Pushed Upward in November as Decode Collapsed | GenomeWeb

NEW YORK (GenomeWeb News) – Shares of Sequenom climbed 49 percent during the month of November as the firm tries to rebound from a clinical study scandal that led to the dismissal of senior executives at the firm two months ago.

Sequenom led the 34 stocks that comprise the GenomeWeb Daily News Index, while Decode Genetics' shares dropped 88 percent as the firm filed for Chapter 11 bankruptcy protection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.